insights_auto
Üldprognoos: 30.8% optimistlik·3.9% pessimistlik
Ava analüüschevron_right
GSK:NYSE
GSK plc
48,59 $
arrow_upward
+1,60%(+0,76) 1 p
20. nov, 10:41:34 GMT −5 · USD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse GSK põhistatistika genereerimine…
Ava
48,21 $
Kõrge
48,74 $
Madal
48,21 $
Turu kapit.
98,73 mld
Keskm. maht
4,56 mln
Maht
434,23 tuh
Dividend
3,78%
Kvartaalne dividend
0,46 $
Dividendikuupäev
12. nov 2026
Hinna ja tulu suhe
17,38
52 näd kõrgeim
61,70 $
52 näd madalaim
45,82 $
Aktsiatulu
2,80 $
Beeta
0,20
Käibivad aktsiad
2,02 mld
Töötajate arv
67 tuh
Ava
48,21 $
Kõrge
48,74 $
Madal
48,21 $
Turu kapit.
98,73 mld
Keskm. maht
4,56 mln
Maht
434,23 tuh
Dividend
3,78%
Kvartaalne dividend
0,46 $
Dividendikuupäev
12. nov 2026
Hinna ja tulu suhe
17,38
52 näd kõrgeim
61,70 $
52 näd madalaim
45,82 $
Aktsiatulu
2,80 $
Beeta
0,20
Käibivad aktsiad
2,02 mld
Töötajate arv
67 tuh
Uudised
Veebiallikatest ja uudistepartneritelt
ad-hoc-news.de
·
4 tunni eest
GSK stock gains Japan orphan status for velzatinib in GIST
www.marketscreener.com
·
6 tunni eest
GSK lifted by tuberculosis drug, Ubisoft's stock-market massacre
Zacks
·
18 tunni eest
Top Analyst Reports for Berkshire Hathaway, JPMorgan & Procter & Gamble
Traders Union
·
1 päeva eest
Why is GSK stock down 1.7% today?
Profiil
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Teave üksuse GSK plc kohta
TegevjuhtEmma Walmsley | Emma Walmsley
Töötajad66,8 tuh
Asutatud27. dets 2000
Peakontorid-
SektorHealth Care
Valdkond-
Veebisaitgsk.com